Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
<p>Abstract</p> <p>Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of coronary artery disease. However, despite increasing use of statins, a significant...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2006-09-01
|
| Series: | Cardiovascular Diabetology |
| Online Access: | http://www.cardiab.com/content/5/1/20 |